Upcoming Webinars

Extensive manipulation, mechanical force, and labelling methods used to enrich cells activate transcriptional programs that mask molecular profiles truly significant to any underlying disease. The consequence is identification of drug targets that are not relevant to the biological process under study. Based on Nakhoda and Olszanski, 2022 (Addressing Recent Failures in Immuno-Oncology Trials to Guide […]

From human B cells to engineered antibodies, IgGenix is taking a novel approach towards breaking through the last frontier of immunology: allergies. By reengineering key antibodies in the allergic cascade, this biotech company is developing a first-in-class therapy for the millions of people whose daily lives are limited by food allergies and other severe allergic […]

Opto B Discovery on the Beacon optofluidic system is designed to enable rapid selection of lead candidates by function-forward screening of B cells in under one week. This presentation will introduce Berkeley Lights’ newest antibody discovery workflow, the Opto Memory B Discovery workflow, and share how customers are using the workflow to screen rabbit memory […]

Single cell and spatial tools from 10 X Genomics are designed to deliver powerful, multiomic insights from complex disease samples that enable you to confidently fuel your target identification pipeline with the most promising candidates. Resolving complex biology with single cell and spatial multiomics was presented by Stephen Hague, Managing Lead Science & Technology Advisor […]

Drug discovery and development is a challenging multiparameter optimisation problem. Harnessing the power of artificial intelligence (AI) can help accurately predict the behaviour and properties of small molecules. In this on-demand webinar from X-Chem you will see: How AI and DNA-encoded library (DEL) screening are transforming early phase drug discovery How this can impact all stages […]

Antibodies are critical reagents applied in multiple biological areas, such as scientific research, therapeutics, and diagnosis. High-quality and reliable antibody reagents are the foundation of good assay performance. To learn more generating and validating critical antibody reagents view this free event hosted by DDW and supported by Sino Biological. The webinar took place on 16 June […]

View this webinar by DDW and supported by Horizon Discovery which examines CRISPR-Cas9 screening and how it offers a powerful approach to advancing drug discovery and the understanding of genetic disease. The event took  place on 9 June 2022. View the webinar here. Joanna Gawden-Bone, Manager, Cell Based Screening, Horizon Discovery will explain how leveraging CRISPR-Cas9 […]

Cellular therapeutics like CAR-T have revolutionised cancer treatment and hold immense promise in other areas of unmet medical need. Developing a new therapeutic cell line is no small task and requires the design and tracking of molecular tools, viral vectors, pluripotent stem cells and more. With projects spanning weeks and potentially multiple scientists, how can […]

DDW was delighted to work with CN Bio on an exclusive event which focussed on novel approaches to human lung disease modelling.  The free event took place on 29 March at 3pm.  It covered:  Accelerating the discovery of new therapeutics for treatment of lung injuries using patho/physiology mimicking models. (Speaker Professor Wojciech Chrzanowski, Faculty of […]

In this free webinar, Dr. Christoph Herbel presents a newly developed workflow which combines flow cytometry–based screenings with high-parameter imaging to identify and validate new tumour markers in an unbiased approach.   The event, Kill the tumour, spare the healthy tissue. Ultra high-content imaging enables target discovery for CAR T cell therapy, was hosted by DDW and supported by Miltenyi Biotec.  It took place on 14 Dec, 4PM GMT, 5PM CET.  Watch on Demand […]

Emerging advancements in protein biotherapeutics are driving the need for more sensitive and accurate bioanalytical methods for their quantification. Serving as an orthogonal technology to the traditional ligand binding assays (LBAs), LC-MS has been routinely adopted for quantitative measurement of protein levels in bioanalytical laboratories. While various MS approaches have been investigated by researchers, bottom-up […]

Advances in treatments for human diseases, including cancer, rely on the ability to gain detailed information into the function, modulation, and variation of the immune system in response to stimuli or immunological challenge. Insights derived from these data have, for example, revolutionized cancer treatment by enabling the development of adoptive cell transfer therapies, such as […]

Many small molecule inhibitors have been approved as cancer therapeutics, but they can confer mutation-based drug resistance and many potential cancer targets remain “undruggable”. One emerging cancer therapeutic strategy that shows promise for drug development is the use of targeted protein degradation (TPD). This approach has many advantages, including the ability to aim at previously […]